N
ORGO icon

Nuveen’s Organogenesis Holdings ORGO Stock Holding History

Nuveen’s Portfolio ORGO Stock Details ORGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$447K Sell
188,745
-85,230
-31% -$295K ﹤0.01% 2885
2025
Q4 		$1.42M Buy
273,975
+115,890
+73% +$562K ﹤0.01% 2444
2025
Q3 		$667K Hold
158,085
– – ﹤0.01% 2797
2025
Q2 		$579K Sell
158,085
-13,691
-8% -$51K ﹤0.01% 2835
2025
Q1 		$742K Sell
171,776
-166,280
-49% -$671K ﹤0.01% 2760
2024
Q4 		$1.08M Sell
338,056
-436,307
-56% -$1.46M ﹤0.01% 2679
2024
Q3 		$2.21M Buy
774,363
+592,256
+325% +$1.66M ﹤0.01% 2366
2024
Q2 		$510K Hold
182,107
– – ﹤0.01% 2986
2024
Q1 		$517K Hold
182,107
– – ﹤0.01% 2964
2023
Q4 		$745K Sell
182,107
-52,890
-23% -$148K ﹤0.01% 2858
2023
Q3 		$747K Buy
234,997
+53,772
+30% +$171K ﹤0.01% 2691
2023
Q2 		$602K Hold
181,225
– – ﹤0.01% 2867
2023
Q1 		$386K Sell
181,225
-83,320
-31% -$206K ﹤0.01% 2867
2022
Q4 		$712K Sell
264,545
-120,302
-31% -$351K ﹤0.01% 2804
2022
Q3 		$1.25M Sell
384,847
-16,318
-4% -$73.7K ﹤0.01% 2647
2022
Q2 		$1.96M Sell
401,165
-486,136
-55% -$2.99M ﹤0.01% 2443
2022
Q1 		$6.69M Sell
887,301
-218,252
-20% -$1.69M ﹤0.01% 1902
2021
Q4 		$10.1M Buy
1,105,553
+81,588
+8% +$867K ﹤0.01% 1683
2021
Q3 		$17.1M Buy
1,023,965
+103,745
+11% +$1.61M 0.01% 1385
2021
Q2 		$15.3M Sell
920,220
-45,995
-5% -$857K ﹤0.01% 1577
2021
Q1 		$17.6M Buy
966,215
+884,258
+1,079% +$12M 0.01% 1423
2020
Q4 		$617K Buy
81,957
+35,474
+76% +$168K ﹤0.01% 2981
2020
Q3 		$178K Buy
46,483
+483
+1% +$1.91K ﹤0.01% 3172
2020
Q2 		$177K Buy
46,000
+19,740
+75% +$71.2K ﹤0.01% 3116
2020
Q1 		$85K Sell
26,260
-227
-0.9% -$972 ﹤0.01% 3082
2019
Q4 		$127K Hold
26,487
– – ﹤0.01% 3114
2019
Q3 		$174K Hold
26,487
– – ﹤0.01% 3132
2019
Q2 		$201K Buy
+26,487
New +$195K ﹤0.01% 3174

Other funds holding ORGO

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Nuveen's ORGO Position: Q1 2026 in Review

Nuveen reduced its Organogenesis Holdings (ORGO) stake by 31% in Q1 2026, selling an estimated $295K and leaving 188,745 shares worth $447K. The position accounts for ﹤0.01% of the portfolio, ranked #2885.

Nuveen first reported a position in ORGO in Q2 2019 and has held it in 28 quarters since. The position peaked at $17.6M in Q1 2021. 121 funds tracked by Wall St. Rank hold ORGO as of Q1 2026.

  • Nuveen held 188,745 shares of Organogenesis Holdings worth $447K as of Q1 2026.
  • Nuveen sold 85,230 Organogenesis Holdings shares in Q1 2026, an estimated $295K.
  • Organogenesis Holdings made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2885 holding.
  • Nuveen first reported a position in Organogenesis Holdings in Q2 2019 and has held it in 28 quarters since.
  • Nuveen's Organogenesis Holdings position peaked at $17.6M in Q1 2021.
  • 121 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.